Nuvectis Pharma, Inc. (NVCT) — 10-Q Filings
All 10-Q filings from Nuvectis Pharma, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 5, 2026
-
Nuvectis Pharma's Losses Widen Amid Soaring R&D Costs
— Nov 4, 2025 Risk: high
Nuvectis Pharma, Inc. (NVCT) reported a significant increase in net loss for the three and nine months ended September 30, 2025, primarily driven by increased r -
Nuvectis Pharma's Q2 Loss Widens Amidst Capital Raises
— Aug 5, 2025 Risk: high
Nuvectis Pharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a net -
Nuvectis Pharma Q1 2025: No Revenue, Focus on Capital
— May 6, 2025 Risk: high
Nuvectis Pharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported $0 in revenue for the first quarter of 2025, consist -
Nuvectis Pharma Q3 2024 Update: Assets $19M, Liabilities $1.4M
— Nov 5, 2024 Risk: medium
Nuvectis Pharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $18,985,324 and total liabilities of $1,402, -
Nuvectis Pharma Files Q2 2024 10-Q
— Aug 6, 2024 Risk: high
Nuvectis Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported a net loss for the quarter. Key financial figures include cash an -
Nuvectis Pharma Files 10-Q for Period Ending March 31, 2024
— May 7, 2024 Risk: low
Nuvectis Pharma, Inc. (NVCT) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Nuvectis Pharma reported total assets of $17,418,886 as of March 31, 2
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX